skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major developments in the business week ended 21 August 2020.

Making headlines this time are two targeted acquisitions by big pharma, negative US FDA decisions and the outlook for the COVID-19-related business.

Stories mentioned in this episode:

(Also see "J&J Seeks Command Position In FcRn Space With Momenta Buyout" - Scrip, 19 Aug, 2020.)

(Also see "Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn" - Scrip, 17 Aug, 2020.)

(Also see "Not Such A Sure Thing: FDA Knocks Back BioMarin’s Roctavian" - Scrip, 19 Aug, 2020.)

(Also see "Gilead’s RA Hopeful Filgotinib Hit By Complete Response Letter" - Scrip, 19 Aug, 2020.)

(Also see "Can Moderna Meet Its COVID Vaccine Expectations?" - Scrip, 17 Aug, 2020.)

 

Pharma Intelligence · Scrip’s Five Must-Know Things – 24 August 2020

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: